Finance Committee
- Referred To
Introduced: Jan 23, 2025
Latest action date: Jan 23, 2025
Current stage
In committee
The most advanced recorded stage is committee consideration.
Introduced
Jan 23, 2025
Latest action
Jan 23, 2025
Recorded roll calls
0
Civixly topics
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Sep 13, 2026.
Newest action first. Action language comes from the official Congress.gov record.
Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
Introduced in Senate
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
0 comments
Loading comments...